A small exploratory clinical trial conducted by Dr. Gary E. Gibson’s laboratory at the Burke Neurological Institute in collaboration with physicians at the Burke Rehabilitation Hospital, suggests that Benfotiamine is safe and potentially efficacious in improving cognitive outcomes among people living with Mild Cognitive Impairment and mild Alzheimer’s disease (AD).
On Wednesday, November 18, 2020, Dr. Dianna Willis spoke about life of a scientist to children of the Kliptown Youth Program in South Africa, an educational program that helps boost academic excellence among very disadvantaged children.
Very recently, the Prusky Lab has resumed limited clinical studies on children at Blythedale Children’s Hospital and adults at Burke Neurological Institute. “I am most proud of lab member’s ability to adapt to the peculiar circumstances they have found themselves in, and make outstanding progress.,” shared Dr. Glen Prusky.
As we carry on with our mission during the COVID-19 pandemic, Burke Neurological Institute (BNI) is slowly and safely bringing back laboratory personnel to campus.
The Friel Lab has quickly adjusted our daily work focus and our long-term vision for clinical trials. They are grateful for the opportunity to focus on data analysis and writing papers from a recently completed clinical trial.
